GRAND RAPIDS, Mich., Nov. 13, 2025 /PRNewswire/ — HAPPE Spine, an early-stage company advancing clinical outcomes with a proprietary biomaterial and manufacturing platform to create osseointegration implants, announces that the INTEGRATE®-C Interbody Fusion System has been implanted in more than 1,000 patients, demonstrating clinical adoption of the HAPPE® platform in more than 30 surgeon users and 40 installations. at the national level.
Dr. George S. Naseef, MD, president of the Advanced Spine Center and interim chair of the Department of Orthopedic Surgery at Morristown Medical Center in New Jersey, said, “I am extremely satisfied with HAPPE INTEGRATE®-C. In my patients, I see earlier fusion and higher fusion rates compared to 3D printed metal devices, especially in multi-level cases. Postoperative imaging is not inhibited by metal artifacts or the interference fit of the INTEGRATE®-C. in the disk space feels more stable compared to the PEEK devices I have used.”
HAPPE Spine closed an oversubscribed bridge financing round earlier this year to support continued clinical validation of the HAPPE platform on the INTEGRATE®-C interbody fusion system and expansion of manufacturing capabilities to support commercial growth and future product offerings.
HAPPE Spine also announces the completion of the MedTech Innovator 2025 accelerator cohort. HAPPE was one of 65 companies (representing the top 4% of nearly 1,500 global applicants) chosen to participate in this year’s program. MedTech Innovator is the world’s largest medical technology startup accelerator and has more than 700 alumni companies that have collectively raised more than $10 billion in follow-on funding and brought more than 500 products to market.
About HAPPE spine:
Our vision is to serve many HAPPE patients and healthcare providers with innovative orthopedic implants that improve clinical outcomes. To this end, HAPPE Spine is a medical device development company that designs and manufactures orthopedic and spinal implants using the proprietary hydroxyapatite porous polyetheretherketone (HAPPE®) biomaterial platform. HAPPE® looks and acts like a biological product, because it has a spongy microporosity with hydroxyapatite embedded and exposed on all surfaces. HAPPE® actively participates in the healing process, confirmed by strong internal and subsequent bone growth, in three preclinical studies. In vitro performance or animal studies may not be representative of clinical performance.
Learn more about HAPPE Spine and the HAPPE® biomaterials platform at happeortho.com.
SOURCE HAPPE
